Gossamer Bio(NASDAQ) GOSS

Gossamer Bio develops medicines for people with serious lung and immune diseases. Its main products aim to help those with rare lung conditions and immune system disorders. The company focuses on treatments that target disease at its source, aiming to improve daily life for patients.

Lab Bench to Bedside: Gossamer’s Main Offerings

• Seralutinib (GB002): Inhaled treatment for pulmonary arterial hypertension, a rare lung disease; 100% of 2025 revenue from related collaboration.
• GB004: Oral therapy for inflammatory bowel disease, targeting gut inflammation in patients with chronic digestive issues.
• GB5121: Oral drug for primary central nervous system lymphoma, a rare brain cancer.
• GB7208: Oral treatment for multiple sclerosis, an immune system disorder affecting the brain and nerves.
• RT234: Inhaled, on-demand therapy for rare lung diseases, under option agreement for future development.

Growth Spurts and Strategic Moves

• Signed global partnership with Chiesi in May 2024 for seralutinib development and commercialization.
• Received $160 million upfront from Chiesi in 2024, with additional milestone payments possible.
• Entered option agreement with Respira Therapeutics for RT234 in 2025.
• Launched Phase 3 clinical trials for seralutinib in 2025; paused one trial in early 2026.
• Reduced workforce by 48% in March 2026 to preserve cash resources.

Why Gossamer Catches the Eye

The company specializes in inhaled and oral drugs for rare diseases, using targeted science to address unmet needs. Its partnership model shares development costs and risks with larger pharmaceutical firms. Gossamer relies on collaborations and licensing to advance its pipeline and manage expenses.

Five Things You Need to Know

• 2025 revenue was $48.5 million, down 57.8% from 2024 due to one-time payments.
• All 2025 revenue came from the Chiesi partnership; no product sales yet.
• Net loss was $170.4 million in 2025, up from $56.5 million in 2024.
• Cash and marketable securities totaled $136.9 million at December 31, 2025.
• Convertible debt of $200 million matures in 2027, raising refinancing concerns.

Bottom Line

Gossamer Bio has evolved through partnerships and a focused drug pipeline. The company faces financial pressures but continues to pursue treatments for rare and serious diseases.